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 25 
Abstract 26 
Long-term peritoneal dialysis (PD) therapy results in functional and structural 27 
alteration of the peritoneal membrane, including epithelial-to-mesenchymal 28 
transition (EMT). Interleukin 6 (IL-6) is a local pleiotropic cytokine, 29 
hypothesized to play an important role in EMT. This study was designed to 30 
investigate the role of IL-6 in EMT and peritoneal membrane dysfunction in 31 
long-term PD patients by assessing the level of IL-6 in dialysate and exploring 32 
the relationship between IL-6, the related signaling pathway JAK2/STAT3, and 33 
EMT, using in vitro cellular and molecular techniques. Plasma and dialysate 34 
levels of IL-6 were significantly higher in PD ultrafiltration failure patients 35 
compared to those in patients without ultrafiltration failure and were negatively 36 
correlated with measures of PD adequacy. In vitro, IL-6 treatment changed 37 
human peritoneal mesothelial cell phenotype from a typical cobblestone-like to 38 
a fibroblast-like appearance and increased cell viability. IL-6 treatment 39 
increased α-SMA and VEGF expression but decreased E-cadherin expression. 40 
IL-6 treatment activated the JAK/STAT signaling pathway. However, the 41 
JAK2/STAT3 inhibitor WP1066 prevented IL-6-induced activation of the 42 
JAK2/STAT3 pathway and EMT. We conclude that IL-6 promotes the EMT 43 
process, possibly by activating the JAK2/STAT3 signaling pathway. IL-6 may 44 
serve as a novel therapeutic target for preventing EMT, and preservation of the 45 
peritoneal membrane may arise from these studies. 46 
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 53 
Introduction 54 
 55 
Peritoneal dialysis (PD) has drawn increasing attention as a common 56 
therapeutic method for end-stage renal disease (ESRD) other than 57 
hemodialysis and renal transplantation. However, long-term PD therapy is 58 
known to result in functional and structural alterations in the peritoneal 59 
membrane (7). Peritoneal pathology can be induced by several stresses 60 
inherent in PD therapy, for example exposure of the peritoneal membrane to 61 
PD fluid, catheter trauma, and peritonitis (26).  62 
 63 
Interleukin 6 (IL-6) is a pleiotropic cytokine that plays an important role in 64 
multiple pathological and physiological processes. It was found that increased 65 
circulating level of IL-6 predicted poor outcome in patients with haemodialysis 66 
and PD (21). In a model of acute peritoneal inflammation, fibrosis was strictly 67 
dependent on IL-6 via IL-6-mediated T helper 1 cell effector commitment and 68 
the emergence of STAT1 (signal transducer and activator of transcription-1) 69 
activity within the peritoneal membrane (8). It was observed that IL-6 levels 70 
were higher in drained dialysate than in the circulation, suggesting that the 71 
peritoneal membrane produces local IL-6 during PD (19). 72 
 73 
The epithelial-to-mesenchymal transition (EMT) is a process by which 74 
epithelial cells lose their cell polarity and cell-cell adhesion and gain migratory 75 
and invasive properties to become mesenchymal stem cells. EMT is essential 76 
for numerous physiological and pathological processes including wound 77 
healing (31), fibrogenic diseases (e.g. peritoneal fibrosis, glomerular fibrosis), 78 
and renal dysfunction in diabetic nephropathy (1，11). Several biomarkers for 79 
EMT have been identified, such as the loss of the E-cadherin (an epithelial 80 
adhesion protein), the upregulation of the α-smooth muscle actin (α-SMA, a 81 
mesenchymal marker) and the upregulation of the vascular endothelial growth 82 
factor (VEGF, a signalling protein involved in both vasculogenesis and 83 
angiogenesis) (34). 84 
 85 
The Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) 86 
pathway is a pleiotropic cascade essential to signal transduction of cytokines 87 
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from the cell membrane to the nucleus. It has been reported to mediate 88 
various cellular functions, including gene activation and cell proliferation, 89 
differentiation and apoptosis (6). JAK/STAT pathway contributed importantly to 90 
synthesis of extracellular matrix proteins (29). The analysis of glomeruli and 91 
tubulointerstitium in kidney biopsies in diabetic nephropathy patients exhibited 92 
increased expression of JAK/STAT pathway (2).  93 
 94 
IL-6 was associated with increased expression of several pro-fibrotic (18) and 95 
pro-inflammatory genes (25), and was found as a promoter of the JAK/STAT 96 
pathway (14). Recent study showed that IL-6 can specifically activate STAT3 97 
via its corresponding receptor (IL-6R), and therefore can lead to activation of 98 
the JAK/STAT signaling pathway (30). In the research area of PD care, despite 99 
the evidence of EMT of peritoneal mesothelial cells in patients undergoing PD, 100 
few studies exist on the relationship between IL-6, the related signaling 101 
pathway (JAK2/STAT3) and the EMT. 102 
 103 
The objective of the current study therefore was to investigate the relationship 104 
between IL-6 and peritoneal membrane injury and the possible mechanism of 105 
IL-6-induced EMT through the JAK2/STAT3 signaling pathway. WP1066, an 106 
inhibitor of JAK2/STAT3, was used to investigate the role of JAK2/STAT3 in 107 
the process of EMT. 108 
 109 
Materials and methods 110 
Clinical epidemiology 111 
Patients 112 
A cohort consisted of 40 ESRD patients between 1st of September 2015 and 113 
31st August 2016 were recruited, from the Nephrology Centre of the First 114 
Affiliated Hospital of Zhengzhou University, Henan, China. The study was 115 
approved by the Ethics Committee of Zhengzhou University. Written informed 116 
consent was obtained from all patients before enrollment.  117 
Patient recruitment criteria are shown in Table 1. Patients were separated into 118 
2 groups [ultrafiltration failure (UFF) and adequate UF], according to the 119 
International Society for PD guidelines (16), which are based on peritoneal 120 
equilibration test (PET) for volume and small solute clearance. After 2000 ml of 121 
4.25% dextrose-containing dialysate is left in the peritoneal cavity for 4 hours, 122 
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less than 400 ml of UF indicates UFF, and dialysate/plasma creatinine ratio 123 
(D/PCr) of more than 0.7 is consistent with the rapid small molecule transport 124 
status often seen in UFF. Patient data included demographic-clinical [age, 125 
gender, BMI, body surface area (BSA), PD duration], laboratory (serum 126 
albumin, Hs-CRP, hemoglobin) and PD adequacy measures (total Kt/v urea, 127 
peritoneal Kt/v urea, renal Kt/v urea, urine output, 24 hours ultrafiltration, 128 
dialysate glucose exposure), the peritoneal equilibration test (PET) (4 hours 129 
ultrafiltration, D/PCr), and the plasma and dialysate IL-6 levels .  130 
 131 
IL-6 level 132 
ELISA was used to measure the level of IL-6 in collected plasma and 133 
peritoneal dialysate fluid (PDF) samples according to manufacturer’s 134 
instructions (CSB-E04638h, CUSABIO, Wuhan, China). Plasma was taken 135 
during peritoneal equilibration test and immediately frozen at −80°C until 136 
analysis. PDF was collected after overnight dwell (8-10 hours) before stored in 137 
at -80°C. Samples were thawed once only during the aliquoting process prior 138 
to analysis. Each sample was examined in duplicate. A Bio-Rad well-reader 139 
(iMark, Bio-Rad, Hercules, CA, USA) was used with the absorbance at 450 nm. 140 
Since the dialysate IL-6 level was influenced by ultrafiltration volume, it was 141 
assessed as IL-6AR (IL-6 Appearance rate), calculated by dialysate 142 
concentration×drained volume/dwell time (pg/min).  143 
 144 
Cellular and molecular biology 145 
Cell 146 
HPMCs were obtained Professor Pierre Ronco (TENON, Paris, France). Cells 147 
were routinely cultured in Dulbecco’s modified Eagle's medium (DMEM, 148 
HyClone, Logan, Utah) supplemented with 10% fetal bovine serum (FBS, 149 
Bioland, San Diego, California, United States), 100 UI/mL penicillin and 100 150 
μg/mL streptomycin. Recombinant human IL-6 (Peprotech, New Jersey, 151 
United States) was dissolved in DMEM. 152 
 153 
MTT assay 154 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St. 155 
Louis, MO, USA) was used. HPMCs were seeded into a 96-well plate 156 
(approximately 4,000 cells per well) and cultured to 40%–50% confluence. 157 
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Twenty μL of MTT (5 mg/mL) was added to each well before further incubated 158 
for another 4 hours. Subsequently, 100 μL of dimethyl sulfoxide (DMSO) was 159 
added to each well and mixed thoroughly, after culture medium was discarded. 160 
Wells were then read at 490 nm using a microplate reader (iMark, Bio-Rad, 161 
Hercules, CA, USA). 162 
 163 
Western blotting 164 
Protein from HPMCs was homogenized in lysis buffer and was quantified. 165 
Each protein sample (30 µg) was separated by 10% SDS-PAGE and 166 
transferred onto a nitrocellulose membrane. At 4°C, the membrane was 167 
simultaneously exposed overnight to mouse anti-α-SMA monoclonal antibody 168 
(Wuhan Boster Biological Technology Ltd., Wuhan, China) in a 1:500 dilution, 169 
to rabbit polyclonal anti-E-cadherin antibody, rabbit polyclonal anti-VEGF 170 
antibody, rabbit polyclonal anti-JAK2 antibody (Proteintech, Manchester, UK) 171 
and rabbit polyclonal anti-phospho-JAK2 antibody (Beijing Biosynthesis 172 
Biotechnology Co. LTD., Beijing, China) in a 1:1000 dilution, to rabbit 173 
monoclonal anti-phosphor-STAT3 (S727) antibody (Abcam, Cambridge, MA, 174 
USA) and rabbit polyclonal anti-STAT3 antibody (Proteintech, Manchester, UK) 175 
in a 1:5000 dilution, and to mouse monoclonal anti-β-actin antibody (Wuhan 176 
Boster Biological Technology Ltd., Wuhan, China) a 1:4000 dilution. After 177 
rinsing with 1×TBS, 0.1% Tween-20 solution four times every 5 minutes, each 178 
membrane was incubated with horseradish peroxidase-conjugated secondary 179 
antibody, goat anti-rabbit IgG or goat anti-mouse IgG (1:10,000 in dilution, 180 
Proteintech, Manchester, UK) for 1 hour at room temperature. After another 181 
wash with 1×TBS, 0.1% Tween-20 solution four times every 5 minutes,  data 182 
were analysed using an enhanced chemiluminescence Western blot detection 183 
system (FluorChem E, proteinsimple, USA).  184 
 185 
RNA extraction and quantitative real-time PCR 186 
Total cellular RNA was extracted using RNAiso Plus (Takara Bio, Inc., Shiga, 187 
Japan), and contaminating DNA was removed using RNAase-free DNase. The 188 
DNA-free RNA was reverse-transcribed into cDNA using the RevertAid First 189 
Stand cDNA Synthesis Kit (Thermo Fisher Scientific Inc., Massachusetts, 190 
United States). Real-time fluorescence quantitative PCR was performed on 191 
the 7500 Fast Real-Time PCR system using SYBR Green as double-stranded 192 
DNA-specific dye in accordance with the manufacturer’s instructions (Life 193 
Technologies, Thermo Fisher Scientific, MA, USA). All primers used in the 194 
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PCR were designed using the Primer Express 2.0 software (Applied 195 
Biosystems) and checked for homology using BLAST (see Table 2). The 196 
relative mRNA expression level of the target genes in each sample were 197 
calculated using the 2−ΔΔCT method.  198 
 199 
WP1066 200 
WP1066 (Selleck Chemicals LLC, USA) is an effective STAT3 pathway 201 
inhibitor (23,27), a small molecule that can selectively block the 202 
phosphorylation of JAK2 and STAT3. 203 
 204 
Statistical analysis 205 
Data (continues variable) were expressed as mean with standard deviation 206 
(SD) or median with interquartile range (IQR) dependent on the data 207 
distribution. Comparison between two groups was analysed using Student’s T 208 
or Mann Whitney test dependent on the data distribution. Pearson’s correlation 209 
test was used to assess possible correlation. A p-value < 0.05, two tailed, was 210 
considered as statistical significance. All statistical analysis was carried out in 211 
SPSS version 17.0.               212 
 213 
Results 214 
Clinical epidemiology 215 
Level of IL-6 in plasma and dialysate in ESRD cohort 216 
Patient demographic and clinical characteristics, and particularly plasma and 217 
dialysate IL-6 levels, stratified by PD/UFF status, are shown in Table 3. The 218 
mean age of the cohort was 42 years, with 18 (45%) females. Not surprisingly, 219 
characteristics demonstrating PD adequacy were different in PD patients 220 
without UFF compared to those with UFF. However, no difference in other 221 
patient characteristics was seen between the two subsets. IL-6 levels (both in 222 
dialysate and plasma) were higher in UFF patients, compared to those in 223 
patients with PD care. 224 
 225 
Table 4 shows the correlation between IL-6 level in dialysate and the selected 226 
patient characteristics. Level of IL-6 in dialysate was positively associated with 227 
PD duration (r = 0.39) and D/PCr (r = 0.63) but negatively correlated with 228 
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measures of PD adequacy in relatively strong relationships (r > 0.3) in all 229 
patients.  230 
 231 
Cellular and molecular biology 232 
Effect of IL-6 on cell morphology and viability 233 
Morphologic change of HPMCs occurred when cells were continuously 234 
stimulated by IL-6 at a level of 50 ng/mL or higher for 5 days, with an apparent 235 
dose-response effect. HPMCs converted into fibroblast-like appearance, from 236 
the initial cobblestone-like cell (see Figure 1A). HPMCs showed an increased 237 
cell proliferation with IL-6 stimulation (50 ng/mL, for 24 hours or longer), 238 
compared to those not exposed to IL-6 but cultured in the same condition (see 239 
Figure 1B). 240 
 241 
Effect of IL-6 on EMT related proteins in HPMC  242 
α-SMA and VEGF was significantly increased whereas E-cadherin was 243 
downregulated with regard to the protein and mRNA expressions in IL-6 244 
stimulated HPMCs at 24 hours (see Figure 2A-B for protein data and 2C-E for 245 
mRNA data), with an apparent dose effect (none vs. 50 ng/mL vs. 100 ng/mL 246 
IL-6). Data also showed that the stimulatory effects were time-dependent up 247 
through the 24 hours tested (see Figure 3). 248 
 249 
Effect of IL-6 on JAK2/STAT3 signaling pathway in HPMC 250 
No difference in the total protein expressions of JAK2 and STAT3 was 251 
observed before and after IL-6 treatment. However, the phosphorylated protein 252 
of JAK2 and STAT3 were significantly increased (see Figure 4 A,C). Data also 253 
showed that the activation effects were dose-dependent (Figure 4 A,B) and 254 
time-dependent (Figure 4 C,D). 255 
 256 
Effect of WP1066 on JAK2/STAT3 pathway and EMT process  257 
P-STAT/STAT3 expression decreased significantly after treatment with 10 µM 258 
WP1066 for 24 hours (Figure 5), confirming that WP1066 was a JAK2/STAT3 259 
inhibitor in our cell system. Therefore, 10 µM WP1066 was used in the 260 
experiments for preventing the JAK2/STAT3 signaling pathway. Figure 6 261 
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shows that treatment of HPMC with 10 µM WP1066 alone for 24 hours did not 262 
alter phosphorylation of JAK and STAT or total JAK and STAT expression, 263 
compared to untreated cells. However, WP1066 prevented IL-6 from 264 
increasing phosphorylation of JAK and STAT. 265 
Addition of WP1066 eliminated the effect of IL-6 on α-SMA, VEGF and 266 
E-cadherin (see Figure 7) and therefore prevented the EMT process.  267 
 268 
Effect of WP1066 on cell morphology and viability 269 
Morphologic change of HPMCs occurred when cells were continuously 270 
stimulated by IL-6 at a level of 50 ng/mL for 5 days. When adding WP1066, the 271 
effect of IL-6 was prevented (see Figure 8A). HPMCs showed an increased 272 
cell proliferation with IL-6 stimulation (50 ng/mL, 24 hours), compared to those 273 
without but cultured in the same condition. But this increasing cell viability was 274 
prevented by WP1066 (see Figure 8B). 275 
 276 
Discussion 277 
PD and hemodialysis are well-established treatments for patients with ESRD. 278 
PD has several advantages compared with hemodialysis, including a simpler 279 
and less invasive procedure and the retention of residual renal function (3,4). 280 
The peritoneum is a membrane with good penetration ability. PD clears 281 
metabolic waste products and toxins and corrects water, electrolyte, and 282 
acid-base disorders, using diffusion, ultrafiltration, and absorption. Peritoneal 283 
ultrafiltration is affected by several factors such as transmembrane pressure 284 
gradient, effective peritoneal surface area and aquaporin function (32). 285 
Continuous exposure to conventional PD solutions contributes to progressive 286 
peritoneal injury, which is an important source of local inflammation that can 287 
result in adverse functional outcome such as higher peritoneal solute transport 288 
rate (PSTR). Higher PSTR is a widely accepted risk factor for mortality and 289 
technique failure in PD patients (24).  290 
 291 
The IL-6 system (both dialysate and systemic) has been found to be 292 
associated with variability in PSTR (13, 20). In our study, the levels of IL-6 293 
(either plasma of dialysate) in patients with UFF were significantly higher than 294 
those in patients without UFF. Furthermore, the dialysate level of IL-6 was 295 
found to be correlated positively with PD duration and D/PCr, and negatively 296 
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with total Kt/v urea, peritoneal Kt/v urea, urine output, 24 hours ultrafiltration 297 
and 4 hours ultrafiltration, suggesting that the dialysate IL-6 level is an 298 
indicator of peritoneal UFF. Our results are in line with those from a previous 299 
study which also showed that increased dialysate IL-6 level was associated 300 
with more years doing PD therapy, and was a predictor of PSTR (5).  301 
 302 
A recent study demonstrated that long-term overexpression of IL-6 might 303 
promote fibrosis by regulating pro-fibrotic T-cell populations (8). In the mouse 304 
model of peritoneal fibrosis, transfer of helper T cell type 1 effector T cell 305 
secreting interferon-γ (IFN- γ) (under IL-6/STAT1 control) restored progression 306 
to fibrosis in IL-6 knockout mouse by altering the normal control by 307 
metalloproteinases of extracellular matrix turnover (8). In our study, HPMCs 308 
treated with IL-6 showed morphological change towards fibroblast-like cells, 309 
suggesting that the presence of overexpressed IL-6 may promote fibrosis in 310 
peritoneal membrane. 311 
 312 
The JAK2/STAT3 signaling pathway affects various basic cell functions in 313 
response to extra-cellular cytokines and growth factors, such as cell growth, 314 
differentiation and death (28). In association with the above classical pathway, 315 
recently the signaling loop of IL-6/ glycoprotein 130 (gp130)/STAT3 was shown 316 
to play a crucial role in the pathogenesis of lung fibrosis (17). In another study 317 
the IL-6/Stat3/Akt signaling axis played a protective role in type 2 318 
pneumocytes by regulating surfactant homeostasis (22). In the mouse model 319 
of gp130F/F, IL-6 trans-signaling via STAT3 is a critical modulator of the 320 
lipopolysaccharide (LPS)-driven pro-inflammatory response through cross-talk 321 
regulation of the TLR4/Mal signaling pathway (9). IL-6 administration in vitro 322 
promoted STAT3 activity and collagen I expression and this study suggested 323 
the multiple roles of IL-6 in renal fibrosis (33).  324 
 325 
There were many proposed pathways associated with the pathogenesis of 326 
peritoneal fibrosis during PD treatment such as the endothelial nitric oxide 327 
synthase (eNOS)-NO signaling pathway (12), Serum response factor (SRF) 328 
signaling (10), the phosphatidylinositol 3-kinase (PI3K)/AKT (also known as 329 
PKB or protein kinase B) signaling pathway (15). However, the specific 330 
involvement of IL-6 in peritoneal fibrosis is poorly understood. In our study, 331 
data showed that the phosphorylation of JAK2 and STAT3 in HPMCs were 332 
significantly increased in response to the treatment of IL-6, implying that IL-6 333 
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may be able to active JAK2/STAT3 signaling in vitro. The current study was the 334 
first to investigate the possible effect of IL-6 on the JAK2/STATA3 in peritoneal 335 
fibrosis. Although the mechanism is still largely unknown, our results at both 336 
the clinical and cellular/molecular levels suggest that IL-6 may be an important 337 
pro-EMT cytokine in PD therapy. This study provides initial and important 338 
insights into the mechanisms of IL-6 in the EMT process of HPMCs and may 339 
lead to therapeutic strategies to slow peritoneal fibrosis.340 
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Figure Legends: 483 
 484 
Figure 1. Effect of IL-6 on HPMC morphology and viability 485 
HPMCs were incubated at 37°C in a 5% CO2 atmosphere in DMEM medium without FBS. 486 
(A) HPMC morphology, (I) without treatment, (II) treated with 30 ng/mL IL-6, (III) with 50 487 
ng/mL IL-6, and (IV) with 100 ng/mL IL-6 for 5 days. Magnification, ×200. 488 
Normal HPMCs showed a cobblestone-like appearance(I), and its morphology had no 489 
obvious changes when cells were treated with 30 ng/mL IL-6. HPMCs which were treated 490 
with increased concentration IL-6 displayed a fibroblast-like morphology (III and IV). N = 6 491 
per group. 492 
(B) HPMC viability, without treatment vs. treated with 50 ng/mL IL-6 for 24, 48 and 72 493 
hours; Absorbance value at 490 nm. 494 
Cell viability was increased by 50 ng/mL IL-6. Compared with the same time, the values of 495 
the experimental groups were higher than that of no treatment group. * Statistical 496 
difference (p < 0.05). N = 6 per group. Data are means ± SE. 497 
 498 
Figure 2. Protein and mRNA expressions of E-cadherin, α-SMA, and VEGF in IL-6 499 
cultured HPMCs at 24 hours 500 
Western blotting analysis for protein expression: (A), raw photo and (B), densitometry 501 
analysis; β-actin as the housekeeping gene to normalize expression level. Real-time 502 
fluorescence quantitative PCR for mRNA expression: (C), for E-cadherin, (D) for α-SMA 503 
and (E) for VEGF; GAPDH as the housekeeping gene to normalize expression level.  504 
The protein and mRNA expression of α-SMA and VEGF increased significantly following 505 
exposure to IL-6, peaking at 100 ng/mL. On the contrary, the expression of E-cadherin 506 
was downregulated by IL-6. *Statistical significant (p < 0.05) vs. no treatment. N = 6 per 507 
group. Data are means ± SE. 508 
 509 
Figure 3. Protein and mRNA expressions of E-cadherin, α-SMA, and VEGF in 50 510 
ng/ml IL-6 cultured HPMCs at 24, 48 and 72 hours 511 
Western blotting analysis for protein expression: (A), raw photo and (B), densitometry 512 
analysis; β-actin as the housekeeping gene to normalize expression level. Real-time 513 
fluorescence quantitative PCR for mRNA expression: (C), for E-cadherin, (D) for α-SMA 514 
and (E) for VEGF; GAPDH as the housekeeping gene to normalize expression level.  515 
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The expression of α-SMA and VEGF increased significantly following exposure to IL-6, 516 
peaking at 72 h respectively. On the contrary, the expression of E-cadherin decreased as 517 
the stimulus time of IL-6 extends. *Statistical significant (p < 0.05) vs. no treatment. N = 6 518 
per group. Data are means ± SE. 519 
 520 
Figure 4. Protein expressions of JAK2 and STAT3 in IL-6 cultured HPMCs at 24, 48 521 
and 72 hours 522 
Western blotting analysis for protein expression: (A,C), raw photo and (B,D), densitometry 523 
analysis; P-JAK2, phosphorylated JAK2; P-STAT3, phosphorylated STAT3; β-actin as the 524 
housekeeping gene to normalize expression level. 525 
(A,B) The relative protein expression of active JAK2/STAT3 increased significantly 526 
following exposure to IL-6, peaking at 100 ng/mL, respectively. * Statistical significant (p < 527 
0.05) vs. no treatment. N = 9 per group. Data are means ± SE. 528 
(C,D) The relative protein expression of active JAK2/STAT3 increased significantly 529 
following exposure to IL-6, peaking at 72 h respectively. * Statistical significant (p < 0.05) 530 
vs. no treatment. N = 9 per group. Data are means ± SE. 531 
 532 
Figure 5. The effect of WP1066 on the expression of P-STAT3/STAT3 at 24 hours 533 
Western blotting analysis for protein expression: (A), raw photo and (B), densitometry 534 
analysis; β-actin as the housekeeping gene to normalize expression level. The relative 535 
protein expression of active STAT3 (phosphorylated/total) decreased significantly in 536 
exposure to 10 μM WP1066; * p < 0.05 (vs. no treatment). N = 12 per group. Data are 537 
means ± SE. 538 
 539 
Figure 6. Phosphorylated and total protein expressions of JAK2 and STAT3 in 540 
HPMCs with IL-6 and WP1066 treatment at 24 hours 541 
Western blotting analysis for protein expression: (A), raw photo and (B), densitometry 542 
analysis; (I) no treatment (without IL-6, without WP1066); (II) IL-6 (with IL-6, without 543 
WP1066); (III) IL-6+WP1066 group (with IL-6, with WP1066); (IV) WP1066 (without IL-6, 544 
with WP1066); β-actin as the housekeeping gene to normalize expression level.  545 
The relative protein expression of active JAK2/STAT3 increased significantly following 546 
exposure to 100 ng/ml IL-6, * Statistical significant (p < 0.05) vs. no treatment. When 547 
adding to 10 μM WP1066, the activation of JAK2/STAT3 which was induced by IL-6 was 548 
prevented obviously. N = 12 per group. Data are means ± SE. 549 
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 550 
Figure 7. Protein expressions of E-cadherin, α-SMA and VEGF in HPMCs with IL-6 551 
and WP1066 treatment at 24 hours 552 
Western blotting analysis for protein expression: (A), raw photo and (B), densitometry 553 
analysis; β-actin as the housekeeping gene to normalize expression level. (I) no treatment 554 
(without IL-6, without WP1066); (II) IL-6 (with IL-6, without WP1066); (III) IL-6+WP1066 555 
group (with IL-6, with WP1066); (IV) WP1066 (without IL-6, with WP1066). Real-time 556 
fluorescence quantitative PCR for mRNA expression: (C), for E-cadherin, (D) for α-SMA 557 
and (E) for VEGF; GAPDH as the housekeeping gene to normalize expression level.  558 
The relative protein and mRNA expression of α-SMA and VEGF increased significantly 559 
following exposure to 100 ng/ml IL-6, which also decreased E-cadherin expression, * 560 
Statistical significant (p < 0.05) vs. no treatment. When adding to 10 μM WP1066, the 561 
expression changes of α-SMA, VEGF and E-cadherin prevented obviously. N = 9 per 562 
group. Data are means ± SE. 563 
 564 
Figure 8. Effect of WP1066 on cell morphology and viability in IL-6 treated HPMCs 565 
HPMCs were incubated at 37°C in a 5% CO2 atmosphere in DMEM medium without FBS. 566 
(A) HPMC morphology, cultured for 5 days; (I) no treatment (without IL-6, without 567 
WP1066); (II) IL-6 (with IL-6, without WP1066); (III) IL-6+WP1066 group (with IL-6, with 568 
WP1066); (IV) WP1066 (without IL-6, with WP1066). Magnification, ×200. (B) HPMC 569 
viability, cultured for 0 and 24 hours; Absorbance value at 490 nm.  570 
IL-6 induced morphologic change of HPMCs and an increased cell proliferation. When 571 
adding WP1066, the effect of IL-6 was prevented. Compared with no treatment, The 572 
morphology and viability of HPMCs had no changes. * Statistical difference (p < 0.05) 573 
between with and without treatment. N = 6 per group. Data are means ± SE. 574 
 575 
 576 
 577 
 578 
 579 
 580 
 581 
 582 
Table  1.  Patient  recruitment  criteria  
  
Eligibility  criteria   Exclusion  criteria  
  
PD  >3  months  
Presence  of  systemic  inflammatory  
disease,  peritonitis  or  fluid  overload  3  
months;;  
≥18  years  old   Malignant  tumor;;  
  
blood  pressure  
<140/90mmHg  
Taking  glucocorticoid  or  
immunosuppressive  agents  during  
the  past  1  year;;  
  
Hemoglobin  A1C(HbA1C)  
<9%  
Acute  cardio  cerebrovascular  events  
that  occurred  in  past  3  months;;  
  
PD  solution:  Dianeal  Baxter  
company  
Multiple  organ  dysfunction  syndrome;;  
Systemic  inflammatory  response  
syndrome.  
  
Inclusion,   meet   all   eligibility   criteria;;   Exclusion,   meet   any   exclusion   criteria.   PD,  
peritoneal  dialysis.  
Table  2.  Sequences  of  mRNA  
  
Gene  Symbol   Forward  Primer(5’-­3’)   Reverse  Primer(5’-­3’)  
E-­cadherin   CTCTTCTCCGCCTCCTTCTT   TGATTCTGCTGCTCTTGCTG  
α-­SMA     AAGATGACCCAGATCATGTT     TCATAGATGGGGACATTGT    
VEGF   ATGACGAGGGCCTGGAGTGT     GGGATTTCTTGGGCTTTCGTTT    
GAPDH   CCTCAAGATCATCAGCAAT   CCATCCACAGTCTTCTGGGT    
Table  3.  Patient  characteristics  and  IL-­6  levels  
  
Characteristics   PD  (n=20)   UFF  (n=20)   p  value  
Clinical-­demographic           
Age,  years   43  ±14   41±15   0.6  
Male   11(55%)   11(55%)   1.0  
BMI   23.6±3.2   22.5±2.5   0.2  
BSA,  m2   1.6±0.5   1.6±0.5   0.9  
PD  duration,  months   24.85(10-­40)   27.20(12-­37)   0.4  
Laboratory  measures           
Serum  albumin,  g/l   30.1±3.5   30.2±3.2   0.9  
Hs-­CRP,  mg/l   4.8±2.8   5.0±2.8   0.8  
Hemoglobin,  g/l   89.6±16.3   88.1±8.9   0.7  
PD  adequacy           
Total  Kt/v  urea   1.8±0.2   1.6±0.2   <0.01  
Peritoneal  Kt/v  urea   1.6±0.2   1.4±0.1   0.04  
Renal  Kt/v  urea   0.2±0.1   0.1±0.1   0.02  
Urine  output,  ml/24h   713(200-­1250)   400(50-­700)   <0.01  
24  h  Ultrafiltration,  ml/24h   628(200-­1300)   100(-­300-­310)   <0.01  
Dialysate  glucose  exposure,  
g/day  
132.2±25.6   142.6±30.5   0.2  
peritoneal  equilibration  test  (PET)           
4  h  Ultrafiltration,  ml/4h   550(400-­750)   30(-­200-­300)   <0.01  
dialysate/  plasma  creatinine  
(D/PCr)  
0.6±0.2   0.8±0.1   <0.01  
IL-­6  level           
Plasma  level  (pg/mL)   20.7±5.0   69.3±16.5   <0.01  
Dialysate  level  	  	  
(IL-­6  Appearance  rate,  pg/min)  
96.1±20.5   448.0±51.6   <0.01  
PD,	   patients	   under	   scheduled	   peritoneal	   dialysis	   care;	   UFF,	   patients	   occurred	   peritoneal	  
ultrafiltration	  failure.	  
Table  4.  Correlation  test  between  IL-­6AR  level  in  dialysate  with  selected  patient  
characteristics  (all  patients  n=40)  
	  
Variable   r   p  value  
BSA   0.09   0.59  
PD  duration   0.39   0.01  
Hs-­CRP   0.27   0.09  
Total  Kt/v  urea   -­0.48   <0.01  
Peritoneal  Kt/v  urea   -­0.33   0.04  
Urine  output   -­0.44   <0.01  
24  hour  Ultrafiltration   -­0.81   <0.01  
4  h  Ultrafiltration   -­0.78   <0.01  
  D/PCr   0.63   <0.01  
	  
PD,   patients   under   scheduled   peritoneal   dialysis   care;;   UFF,   patients   occurred  
peritoneal  ultrafiltration  failure;;  r,  correlation  coefficient.  
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